The Evergreening of Biopharmaceuticals: Time to Defoliate

@article{Lehmann2016TheEO,
  title={The Evergreening of Biopharmaceuticals: Time to Defoliate},
  author={David F Lehmann and Sarabeth Wojnowicz},
  journal={The Journal of Clinical Pharmacology},
  year={2016},
  volume={56}
}
As a successful product approaches its date of patent expiration, chiral switching, that is, the isolation, testing, approval, and marketing of the pharmacologically active stereoselective isomer (enantiomer), termed “evergreening,” allows the manufacturer to maintain market share via exclusivity.1 The marketing of one stereoisomer typically emphasizes a single pharmacometric difference between the active and inactive enantiomer via extrapolation to the bedside.2 On rare occasions, eg, S… Expand
2 Citations

Topics from this paper

ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.
TLDR
A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood. Expand
Lifetime evolution of ADHD treatment
TLDR
A naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan finds stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected. Expand

References

SHOWING 1-10 OF 63 REFERENCES
Escitalopram: Superior to Citalopram or a Chiral Chimera?
TLDR
The manufacturer’s claims of superiority for escitalopram over citaloprams are unwarranted, and the Swedish and Danish drug regulatory authorities reached similar conclusions. Expand
Contrasting properties of albuterol stereoisomers.
TLDR
(S)-albuterol intensifies bronchoconstrictor responses of sensitized guinea pigs and induces hypersensitivity of asthmatic airways; it also promotes the activation of human eosinophils in vitro. Expand
Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern?
  • B. Waldeck
  • Medicine, Chemistry
  • The Journal of allergy and clinical immunology
  • 1999
TLDR
It thus appears that all established pharmacologic effects of racemic beta2-agonists reside in the (R)-enantiomer, with the (S)- enantiomer being virtually inactive. Expand
Putting chirality to work: the strategy of chiral switches
TLDR
Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Expand
Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol.
TLDR
Pre preferential retention of the (S)- compared with the (R)-enantiomer in the lung could lead to accumulation of the(S) enantiomer after long-term use of racemic albuterol. Expand
The Seduction of Biomarkers in the Practice of Medicine and the Tyranny of Power in the Drug Approval Process: Lessons From Niacin
TLDR
Niacin’s lack of impact on clinically relevant cardiovascular outcomes in this clinical trial, despite improvement in both surrogate biomarkers, is consistent with and extends observations from previous reports of the lack of benefit on cardiovascular outcomes when fenofibrate is added to simvastatin, despite a significant reduction in triglycerides. Expand
Chiral switches
TLDR
It is easier to understand "pure" as opposed to "mixture" pharmacology but whether the promise of chiral (and metabolite) switches will translate into real clinical advances remains to be seen. Expand
A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
TLDR
It is suggested that early, regular nebulized beta(2)-agonist and systemic corticosteroid therapy may reduce hospitalization and relapse rates in patients with acute severe asthma. Expand
Escitalopram block of hERG potassium channels
TLDR
Results suggest that escitalopram blocked hERG currents at a supratherapeutic concentration and that it did so by preferentially binding to both the open and the inactivated states of the channels and by inhibiting the trafficking of hERG channel protein to the plasma membrane. Expand
Citalopram and cardiac toxicity
TLDR
A dose-effect relationship for QT prolongation exists across a broad range of citalopram doses, such that caution must be exercised when prescribing high doses or if there are co-existent risk factors forQT effects. Expand
...
1
2
3
4
5
...